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Abstract 
A simple, sensitive and rugged reverse-phase high performance liquid chromatographic method has been 
developed and validated for the determination of rivaroxaban in pure, pharmaceutical formulations and in spiked human 
plasma sample. The separation of rivaroxaban and internal standard was achieved on XDB C18 (150 x 4.6) mm column. 
Mobile phase employed for the study is the mixture of water and acetonitrile in gradient programme. A flow rate of 1 
ml/min was found optimum for the study. Linearity of the proposed method was found to be in the range of 0.05 µg/ml to 
20 µg/ml with r
2
=0.9999. The limit of detection and limit of quantification of the proposed method are found to be 0.015 
µg/ml and 0.046 µg/ml, respectively. Intra-day and inter-day assay relative standard deviations were determined and found 
to be less than 2.0 %. The method has been applied successfully for the determination of rivaroxaban in its pharmaceutical 
formulations and in spiked human plasma samples. 
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1. Introduction 
Rivaroxaban (RVX) is an oral anticoagulant, 
which prevents clotting of blood. The IPUAC name for 
RVX is (S)-5-chloro-N-{[2-oxo-3-[4-(3-oxomorpholin-4-
yl) phenyl]oxazolidin-5-yl]methyl} thiophene-2-
carboxamide. The chemical formula of RVX is as shown in 
Fig. 1. RVX is a reversible, direct factor Xa inhibitor that is 
rapidly absorbed with maximum concentrations in healthy 
and elderly subjects.[1, 2] RVX is found to have anti-
thrombotic effects.[3]  Thrombin multiplication occurs in 
Factor Xa at the rate of 1000
th
 fold.[2, 4] Hence, factor Xa 
plays an important role in treating the thromboembolic 
disorders. The inhibition of factor Xa by RVX is due to its 
binding with S1 and S4 pockets of the enzyme serine 
endopeptidase with high selectivity. [5] Inhibition of factor 
Xa interrupts the intrinsic and extrinsic pathway of the 
blood clotting process, inhibiting both thrombin formation 
and thrombi development.  
In the literature only a few methods for the 
determination of RVX has been reported. They include 
Spectrophotometry, [6] HPLC, [7-11] HPTLC, [12] and 
LC-MS. [13] None of the reported methods doesn’t study 
the determination of RVX in human plasma, whereas the 
proposed method describes the HPLC method for the 
determination of RVX in pure, pharmaceutical 
formulations and spiked human plasma samples. 
 
 
 
 
 
 
 
Figure 1: Rivaroxaban 
 
2. Experimental 
2.1 Reagents and Chemicals 
HPLC grade acetonitrile and methanol were 
purchased from Sigma, purified de-ionized water was 
prepared in the laboratory using Barnstead Nano-pure 
Diamond water purification system (Thermo, Waltham, 
MA). RVX and vemurafenib were kindly provided by 
Apoptex Pharmachem India Pvt Ltd., Bangalore, as gift 
samples. Commercial dosage forms of RVX were 
purchased from the local market. 
2.2 Instrumentation 
The Waters 2690 HPLC system consisted of 
gradient pump with degassing facility and gradient mixer, 
photodiode array detector, an auto sampler and an 
Empower workstation was employed for the study. 
Chromatographic separation was achieved on Agilent, 
Zorbax Eclipse XDB C18 (150 x 4.6) mm, connected with a 
guard column associated with the same bonded phase. The 
mobile phase consisted of water (A-pump) and acetonitrile 
(B-pump) in the gradient program as follows: Time (min) / 
B (%): 0/35, 7.3/35, 8.0/65, 12/65, 12.1/35, 14/35. 1 
ml/min of flow rate was maintained throughout the 
chromatographic run, i.e., 14 min. Sample temperature and 
column temperature were maintained at 15 
0
C and injection 
volume was 20 µl.  
2.3 Preparation of Standard Solution 
RVX stock solution containing 1 mg/ml was 
prepared in methanol:acetonitrile in the ratio of 1:1 and a 
stock solution of vemurafenib (Internal Standard, IS) 
containing 1 mg/ml was prepared in the mixture of water 
and acetonitrile in the ratio of 2:8. The solutions were 
diluted as when required. Standard working solutions were 
prepared individually in the diluent, methanol:acetonitrile 
(1:1). Working solution of each of 250 µg/ml of RVX and 
IS were prepared separately in the diluent. 
2.4 Preparation of Pharmaceutical Formulation 
Twenty tablets of RVX were finely powdered and 
an amount equivalent to the 25 mg of the drug was 
weighed accurately and transferred into a 100 ml beaker. 
The powdered drug was completely disintegrated in the 
diluent, using a mechanical stirrer. The solution was 
filtered through 0.45 µ filter paper and was diluted upto the 
mark of 50 ml with the diluent. 
2.5 Preparation of Spiked Human Plasma Sample 
Saline and sodium citrate solutions were taken in 
dry and evacuated tubes. Human blood samples from 
different healthy volunteers were collected in dry and 
evacuated tubes, after overnight fast, before breakfast. 
Within 1h of plasma collection, the samples were 
centrifuges at 1600 rpm for 12 min. The plasma samples 
were spiked with RVX and IS and were extracted with 
ether. The ethereal layer was evaporated to dryness on a 
water bath at 40 
0
C under the low stream of nitrogen gas. 
The residue was dissolved in the diluents, stored at -20 
0
C 
until further analysis.  
2.6 Validation of the Method 
The validation of the proposed HPLC method was 
carried out according to the Food and Drug Administration 
(FDA) guidelines. [14] Linearity of the proposed method 
was determined by replicate analysis of 6 complete 
standard curves on 6 different days. A linear regression was 
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used to plot the peak area ratio (y) of RVX to IS versus 
RVX concentration. Intra- and inter-day precision and 
accuracy expressed as bias were evaluated at three levels of 
concentrations. Six replicates of each level were assayed in 
one run for the intra-day experiment. Three replicates of 
each level were assayed within six different days for the 
inter-day experiment. Average recovery of RVX was 
determined by comparing the peak area at different 
concentration levels (6 replicates for each level) with those 
obtained by direct injection of the same amount of drug.  
 
3. Results and Discussion 
3.1 Chromatographic Method Development 
Various compounds viz., amoxicillin, cefedroxil, 
valganocyclovir, andrographolide, vemurafenib were tested 
for the purpose of internal standard, but a good 
chromatographic characteristics like ideal retention time, 
resolution, peak shape, etc were observed with 
vemurafenib and hence it was selected as an internal 
standard. The mobile phase was chosen after various trials 
with methanol, water, istopropyl alcohol, acetonitrile, 
triethylamine and various buffers with different pH in 
various proportions. Because of high transparency in UV 
region, acetonitrile was selected with water as the mobile 
phase. For the selected mobile phase in the above 
mentioned gradient program, both RVX and internal 
standard gave good chromatographic separation and 
behavior. The effect of flow rate was examined by varying 
the flow rate of the mobile phase from 0.75 ml/min to 1.50 
ml/min and observed that a flow rate of 1.0 ml/min gave 
optimal signal to noise ratio with a reasonably good 
separation time and hence a flow rate of 1.0 ml/min was 
chosen for the study. The maximum absorption of RVX 
and IS together were found to be at 250 nm and hence this 
wavelength was selected for the experiment. Using C18 
column, the retention times of RVX and IS were found to 
be 5.08 min and 11.95 min respectively. A typical 
chromatogram obtained is shown in Fig. 2.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2: A typical chromatogram showing the separation of RVX and IS 
3.2 Suitability of the Proposed Method 
The system suitability of the proposed method is 
determined. The suitability parameters like resolution, peak 
asymmetry, capacity factor, theoretical plates were 
calculated and are tabulated in Table 1. For a system to be 
suitable for the determination of an analyte, the resolution 
should be more than 1.5, peak asymmetry should be 
between 0.8 and 1.2, and selectivity should be more than 
1.0. The system suitability values of the proposed method 
revealed that, the method is ideal for the determination of 
RVX in pure, bulk and spiked human plasma samples. 
 
Table 1: System suitability parameters 
Parameter RVX IS 
Number of theoretical plates 1589 19778 
Retention time (tR) in min 5.08 11.95 
Resolution               27.48 
Capacity factor (k’) 6.47 16.57 
Selectivity factor (α)              2.56 
Peak asymmetry (AS) 1.08 1.03 
Height equivalent to theoretical plate (H) in mm 0.09 0.01 
 
3.3 Selectivity 
The specificity of the proposed method was 
examined by the injection of different drugs such as 
andrographolide, valganocyclovir, erlotinib, amoxicillin, 
sorafenib cefedroxil, and found they did not interfere in the 
determination of RVX, which was evident from their 
retention times which are different from that of RVX.  
3.4 Linearity 
Linear relationship between the peak area ratio of 
RVX and IS corresponding to concentration of RVX was 
observed. Linearity of the method was determined by 
analyzing different solutions containing 0.05 µg/ml to 20 
µg/ml of RVX and fixed concentration of internal standard 
(5 µg/ml), under the mentioned chromatographic 
conditions. Six independent determinations were carried 
out at each concentration level. Table 2 gives the regression 
line, correlation coefficient, slope, intercept and % RSD. 
An excellent linearity was observed in the range of 0.05 - 
20 µg/ml, as evident by its r
2
 value, 0.9999. 
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Table 2: Linearity, LOD and LOQ 
Parameter Value 
Linearity range (µg/ml) 0.05 - 20 
Regression equation (Y)
a
  
Slope (b) 0.066 
Intercept (c) 0.004 
Correlation coefficient (r
2
) 0.9999 
LOD ( µg/ml) 0.015 
LOQ ( µg/ml
 
) 0.046 
% RSD 1.64 
                     a
Y = Bx + C, where, x is the concentration of RVX in µg/ml. 
 
3.5 Limit of Detection and Limit Quantification 
The limit of detection (LOD) was established at a 
signal-to-noise ratio (S/N) of 3 and the limit of 
quantification (LOQ) was calculated at S/N value of 9. The 
LOD and LOQ values were found to be 0.015 µg/ml and 
0.046 µg/ml, respectively. The values are shown in Table 
2. 
3.6 Precision and Accuracy 
The precision of the proposed method was 
examined by carrying out the analysis on within-day and 
between-day variations of determinations. This was done 
by injecting the RVX at its LOQ level (n=6). The accuracy 
of the proposed method was determined as follows: a 
standard working solution containing 10 µg/ml of RVX 
and 5 µg/ml of internal standard was injected and the 
chromatograms were recorded. This was repeated for 6 
times (n=6). From the respective area counts, the 
concentrations of RVX were calculated using linearity 
curve. The accuracy, defined in terms of percentage 
deviation of the obtained concentration from the actual 
concentration was found to be satisfactory. The precision 
and accuracy data obtained are tabulated in Table 3. 
 
Table 3: Precision and accuracy data for the determination of RVX 
Actual concentration, 
µg mL
-1
 
Intra-day concentration 
measured (n=6) 
 
% 
RSD 
% 
Bias 
Inter-day concentration 
measured (n=3) 
% 
RSD 
% 
Bias 
5 5.03 1.423 0.60 5.06 1.468 1.20 
10 9. 92 1.658 - 0.80 9.96 0.859 - 0.40 
20 19.88 0.925 - 0.60 19.93 1.067 - 0.35 
 
3.7 Recovery Studies 
To study the recovery of the proposed method, 
80%, 100% and 120% of RVX was added to a pre-
analyzed sample. The recovery studies were carried out 
three times over the specified concentration range and the 
percentage recovery was found to be in the range of 
98.85% to 100.82%. 
3.8 Ruggedness of the Method 
The ruggedness of the proposed HPLC method 
was examined by carrying out the analysis of the working 
standard solution by employing the same chromatographic 
conditions and system on different days good consistency 
in retention times and very negligible differences in areas 
were noticed after 48h time period. The % RSD values 
were found to be less than 2.0 for both retention times and 
areas. The good detector responses obtained on different 
days showed that the proposed method is rugged. The 
results are showed in Table 4.    
 
Table 4: Ruggedness of the method 
Parameter RVX IS 
1
st
 day 2
nd
 day 1
st
 day 2
nd
 day 
Area
a
 1328146 1331328 438037 4391029 
SD 14875.24 20103.05 7578.04 72012.88 
% RSD 1.12 1.51 1.73 1.64 
Retention time
a
 5.082 5.076 11.953 11.947 
SD 0.057 0.064 0.090 0.109 
% RSD 1.06 1.26 0.75 0.91 
a
 Average values of six determinations. 
 
4. Applications 
4.1 Analysis of Pharmaceutical Formulations 
The proposed analytical method was applied 
successfully for the analysis of RVX in its pharmaceutical 
formulations. The low values of percentage relative 
standard deviation indicated that the method is highly 
precise for the analysis of RVX in its formulations. The 
results obtained are tabulated in Table 5. 
 
Table 5: Analysis of RVX in its dosage forms 
Tablet Strength, mg Found
a
, mg % RSD % Recovery 
Xraelto 
10 10.08 ± 0.71 0.55 100.80 
15 14.89 ± 0.94 1.28 99.27 
20 19.95 ± 0.82 1.66 99.75 
a
 Mean value of six determinations. 
 
4.2 Analysis of Plasma Samples 
The proposed method was applied successfully for 
the analysis of RVX in spiked human plasma samples. The 
obtained results for the accuracy and precision at three 
different levels in spiked plasma are tabulated in Table 6.   
Low values of % RSD and % Bias revealed that the 
proposed method is highly precise and accurate.  
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5. Conclusion 
A reverse phase HPLC method for the 
determination of RVX in pure, dosage forms and spiked 
human plasma has been developed and validated. The 
proposed method showed good accuracy and precision and 
acceptable linearity. By employing the proposed HPLC 
method, one can detect the RVX as low as 0.015 µg/ml. 
The proposed method is rapid in determining the RVX in 
plasma sample, since plasma sample preparation before 
chromatographic analysis is quite simple. The proposed 
HPLC method could be employed to analyze a large 
number of plasma samples each day in clinical laboratories 
and pharmaceutical dosage forms in routine quality control 
laboratories. Hence the proposed method could be adopted 
for the assay of RVX in plasma samples and 
pharmaceutical formulations. 
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